Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1362758 | Bioorganic & Medicinal Chemistry Letters | 2010 | 5 Pages |
Abstract
This Letter describes the lead discovery, optimization, and biological characterization of a series of substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as potent inhibitors of IGF1R, EGFR, and ErbB2. The leading compound 11 showed an IGF1R IC50 of 12 nM, an EGFR (L858R) IC50 of 31 nM, and an ErbB2 IC50 of 11 nM, potent activity in cellular functional and anti-proliferation assays, as well as activity in an in vivo pharmacodynamic assay.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Gary T. Wang, Robert A. Mantei, Robert D. Hubbard, Julie L. Wilsbacher, Qian Zhang, Lora Tucker, Xiaoming Hu, Peter Kovar, Eric F. Johnson, Donald J. Osterling, Jennifer Bouska, Jieyi Wang, Steven K. Davidsen, Randy L. Bell, George S. Sheppard,